



AUSBIOTECH 2009 PROGRAM*

TUESDAY 27 OCTOBER

8:00am – 7:00pm	<p>Delegate Registration Desk Open <i>Concourse Melbourne Exhibition Centre</i></p>
9:30am – 4:00pm	<p>AUSBIOTECH AUSTRALASIAN LIFE SCIENCES INVESTMENT SUMMIT By Invitation Only</p> <p>AusBiotech Australasian Life Sciences Investment Summit – <i>Rooms 220 and 219, Level 2, MCC</i> AusBiotech Australasian Life Sciences Investment Summit Lunch – <i>Rooms 212 and 213, Level 2, MCC</i> AusBiotech Australasian Life Sciences Investment Summit – One-on-one Partner Meetings - <i>Rooms 218 and 217, Level 2, MCC</i></p> <p><i>Sponsored by Australian Securities Exchange, Australian Trade Commission, Blueprint Life Science Group, RBS Morgan and the Victorian Government</i></p>
9:30am – 5:00pm	<p>SATELLITE EVENTS <i>Melbourne Convention Centre</i> <u>BioBasics in one day: Biotechnology for the non-science professional</u> - <i>Bridge Room, Crowne Plaza Melbourne Hotel</i></p> <p>Tuesday 27 October 8:30am - 4:30pm</p> <p><u>Smart IP Management – putting the IP Manual into practice</u> - <i>Bridge Room, Crowne Plaza Melbourne Hotel</i> Tuesday 27 October 8:30am - 4:30pm</p> <p>UK Trade & Investment presents: <u>Brains of Britain</u> - <i>Room 216, Level 2, MCC</i> Tuesday 27 October 10.00am - 5.00pm</p>
3:00pm – 5:00pm	<p>AUSBIOTECH 2009 TRADE AFTERNOON <i>BioIndustry Exhibition Hall</i></p> <p>The AusBiotech BioIndustry Exhibition is the largest biotechnology exhibition assembled in Australia. The exhibition showcases the latest in business and product services, equipment, instrumentation, devices and state-of-the-art technology. The Trade Afternoon is offered in addition to general access of the BioIndustry Exhibition for exhibitors and delegates. This time has been allocated specifically for exhibitors to invite guests and for graduate and undergraduate students to attend and engage with industry.</p>
3:30pm – 5:00pm	<p>Networking High Tea with Exhibitors <i>Melbourne Exhibition Centre – Exhibition Hall</i></p>

*Conference Program as at 27 October - subject to change

5:00pm – 5:30pm	Coaches to Government House depart Melbourne Convention Centre, Porte Cochere Main Entrance, Convention Centre Place, opposite Hilton South Wharf Hotel
6:00pm – 8:00pm	AUSBIOTECH 2009 WELCOME RECEPTION Professor David de Kretser, Governor of Victoria, Mr Joe Helper MP, Minister for Agriculture and Dr Deborah Rathjen, Chair, AusBiotech Ltd <i>Government House</i> Sponsored by Victorian Government For registered delegates only, name badge and entrée card from Governor required for entry
From 7:00pm	Coaches depart Government House to return delegates to the Melbourne Convention Centre

WEDNESDAY 28 OCTOBER

9:00am – 11:00am <i>Melbourne Convention Centre – Plenary Hall 3</i>	<p>OPENING OF AUSBIOTECH 2009 – Opened by the The Hon Gavin Jennings MLC, Minister for Innovation <i>Melbourne Convention Centre – Plenary Hall 3, Ground Floor, MCC</i></p> <p>AWARD PRESENTATIONS AusBiotech–GSK Student Awards – presented by Dr Ashley Bates, Head of R&D Alliances Australia/NZ, GlaxoSmithKline - Sponsored by GlaxoSmithKline</p> <p>AusBiotech 2009 Excellence Awards – presented by Dr Deborah Rathjen, Chair, AusBiotech Ltd and Dr Bardia Akbari, Global Head Partnering Inflammation and Autoimmune - Roche Sponsored by Roche</p> <p>PLENARY 1 - "What happened to early stage life science investing?" Dr John Diekman, Managing Director, Sam Ventures, United States</p> <p>PLENARY 2 -Presentation title to be confirmed Dr. Richard Shau, General Director of Medical Device Technology Center, Industrial Technology Research Institute, Taiwan</p>			
11:00am – 11:30am	Morning Tea - BioIndustry Exhibition Hall			
11:30am – 1:00pm Concurrent Sessions: Level 2 Melbourne Convention Centre	<p style="text-align: center;">MEDTECH Room 217</p> <p style="text-align: center;">Global Opportunities - AusBiotech / Austrade working together</p> <p>AusBiotech has been selected as the lead organisation to establish an Australian Medical Device Manufacturers cluster, one of the eight successful clusters under the Austrade managed Global Opportunities program (GO). This pilot program aims to help Australian medtech companies to pursue export opportunities in the North American healthcare market, to targeting supply chains supplying medical devices to the government and non-government healthcare sectors</p> <p>Chair: Mr Glenn Cross, Chief Operating Officer, AusBiotech Ltd</p> <p>Speakers: Ms Janelle Casey, Industry Team Leader Health, Biotechnology and Wellbeing, Austrade Mr David Radford, Executive Director & CEO,</p>	<p style="text-align: center;">HUMAN HEALTH Room 219</p> <p style="text-align: center;">Biopharmaceuticals in a post Global Financial Crisis world</p> <p>In the short term, the GFC has stifled funding for early stage biotech. As the market recovers, proposed changes to the US healthcare system could completely transform the biotech-pharma value chain and deal-making drivers. Meanwhile how will pharma address its looming patent cliff and other threats?</p> <p>Chair and Speaker: Mr Peter Molloy, President, Aquarius Consulting <i>"The US after the meltdown: Funding, partnering and health care reform."</i></p> <p>Speakers: Professor Susan Pond <i>"Biotechnology after the Global Meltdown: Building for the future"</i> Mr Lubor Gaal, Head of Europe Search, Strategic Transactions Group, Bristol-Myers</p>	<p style="text-align: center;">AG / INDUSTRIAL / FOOD Room 218</p> <p style="text-align: center;">Advancing the Industrial Biotech Revolution</p> <p>This session will explore the issues of synthetic biology tools and how they are addressing the needs for renewable fuels and chemicals. The commercialization roadmap will be discussed, contrasting partnership approaches with the petrochemical industry. In closing, funding strategies will be considered in the context of feeding the industrial biotechnology revolution.</p> <p>Chair: Damien Perriman, Vice President Business Development, Verdezyn, Inc., United States</p> <p>Speakers: Mr Karl Kelly, Director of Commercial Operations, Clemeon University, South Carolina <i>"Biomass: Opportunities and Risks for</i></p>	<p style="text-align: center;">INVESTMENT / BUSINESS Room 220</p> <p style="text-align: center;">"What are fund managers looking for?"</p> <p>The GFC has changed the world of finance and the world of investing. With panelists of diverse experience through the entire value chain of finance from experienced international venture capitalists, to leading sell-side analysts to public equity fund managers, discover their views on what investors are looking for.</p> <p>Chair: Mr Hershel Berry, Founder & Managing Partner, Blueprint Life Sciences</p> <p>Panelists: Mr Andrew Goodsall, Senior Healthcare Analyst, UBS Healthcare Equity Research</p>

	<p>Nanosonics</p> <p>Mr John Kelly <i>"Developing international partnerships and joint venture strategies to assist in the commercialisation and export of Australian medical device technology"</i></p>	<p>Squibb <i>"Bristol-Myers Squibb - Partnering heritage and strategy to create the next generation BioPharma company."</i></p> <p>Dr. BJ Bormann, Senior Vice President of Business Development & Licensing, Boehringer-Ingelheim <i>"Pharma Investing Today: Against the Current"</i></p>	<p><i>Biochemicals and Green Fuels"</i></p> <p>Professor Lars Nielsen, Chair & Professor in Biological Engineering, Australian Institute for Bioengineering and Nanotechnology <i>'Synthetic Biology Tools for Fueling Opportunities'</i></p> <p>Mr David Theriault, Business Development Leader Emerging Technology, The Dow Chemical Company <i>"Partnering with the Petrochemical Industry"</i></p>	<p>Dr. Sunny Sharma, Senior Managing Director Asia, OrbiMed Advisors</p> <p>Dr Selena Chaisson, Director of Healthcare Investments, Bailard</p> <p>Dr David Collier, Managing Director, CMEA Capital</p>
--	--	---	--	--

1:00pm – 2:00pm Lunch - BioIndustry Exhibition Hall

<p>2:00pm – 3:30pm</p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>MEDTECH Room 218</p> <p>Reimbursement Strategies for Medical Devices</p> <p>After the thrill of invention, the slog of development and innovation and the trials of Regulatory approval comes the key stage - reimbursement. Too often looked upon as a footnote, this is a complex and demanding area which is vital for the commercialisation of innovation and the survival of the innovative company.</p> <p>Chair: Dr Greg Roger, Chief Executive Officer, Advanced Surgical Design Manufacture</p> <p>Speakers: Dr Alan Robertson, Chief Executive Officer, Pharmaxis <i>"Negotiating prices of pharmaceutical products within the European Union"</i></p> <p>Ms Sue O'Malley, Consultant Reimbursement Strategist, Medical Intelligence <i>"Houston - we have a problem! Update on the reimbursement process problems for medical technology in Australia"</i></p> <p>Ms Beth L Roberts, Partner, Hogan and Hartson USA <i>"US Medical Device Reimbursement Basics"</i></p>	<p>HUMAN HEALTH Room 220</p> <p>Biomarkers in Drug Discovery and Development: Commercialisation Pathways and Strategic Partnerships</p> <p>Biomarkers are assuming an increasingly important role in drug discovery and development as well as in the transformation of medical practice. Drug developers are investing heavily in this area as validated biomarkers provide the opportunity for smarter and earlier decision making in R&D and clinical application. Further advances promise to lower the cost and time of drug development by better understanding drug targets and mechanisms of drug action and by enriching clinical trial populations for those patients most likely to benefit from new drugs. This session will discuss recent technological advances, relevant regulatory frameworks, and strategic partnerships that are forging the way to successful development and commercialisation of biomarkers, as well as the many challenges associated with biomarker development, such as protection of intellectual property, clinical validation, education of medical practitioners, and health economics supporting reimbursement.</p> <p>Come and hear the insights of successful companies who are carving a niche in this exciting field.</p> <p>Chair: Dr Colleen Nelson, Executive Director, Australian Prostate Cancer Research Centre (QLD)</p> <p>Speakers:</p>	<p>AG / INDUSTRIAL / FOOD Room 219</p> <p>Food Security and AgBio</p> <p>Food security has become an important topic especially in the face of climate change. This session will explore various aspects on how biotechnology can contribute to food security in Australia and abroad.</p> <p>Chair & Speaker: Dr Michael Gilbert, General Manager, Australian Centre for Plant Functional Genomics <i>"Cereals in Australia: addressing challenges in a stressful climate!"</i></p> <p>Speakers: Dr Ganesh Kishore, CEO Malaysian Life Sciences Capital Fund, Burrill and Company / Malaysian Technology Development Corporation <i>"Green Bio – the basis of sustainable food and nutrition security"</i></p> <p>Dr Harvey Glick, Regional Scientific Affairs Lead, Monsanto</p>	<p>INVESTMENT / BUSINESS Room 217</p> <p>Waging War on Counterfeit Pharmaceuticals: Effective Investigation and Enforcement Across Jurisdictions</p> <p>In this session the focus will be on identifying areas of industry exposure to counterfeiting, including online trade in pharmaceutical products. Tips and traps in anti-counterfeiting and IP enforcement campaigns will be discussed in addition to border control: Australian Customs and World Customs Organisation initiatives to combat trade in pharmaceutical counterfeits; how counterfeits adversely impact upon pharmaceutical businesses; anti-illicit trade strategies and trends; and best practice in investigation and enforcement initiatives.</p> <p>Chair and speaker: Ms Elisabeth White, Partner, Baker & McKenzie</p> <p>Speakers: Mr Bjorn Roberts, Director of Intelligence and Consumer Safety, Australian Customs & Border Protection Service.</p> <p>Mr Ken Taylor, Private investigator, Trade Mark Investigation Services <i>"Tips and traps in anti-counterfeiting and IP enforcement campaigns; and best practice in investigation and enforcement initiatives"</i></p>
--	---	--	--	--

		<p>Mr Gary Breit, Executive Director, University of Manitoba Technology Transfer Office</p> <p>Dr Daniel Chelsky, Chief Scientific Officer, Caprion Proteomics <i>"Industrialized Biomarker Discovery and Validation for Pharmaceutical Drug Development"</i></p> <p>Mr Christopher Boyer, Executive Director, Bio-Link Australia</p> <p>Mr Erinn Broshko, Chief Executive Officer, Med BioGene</p> <p style="text-align: center;"><i>Sponsored by Government of Canada</i></p>		<p><i>Sponsored by Baker & McKenzie</i></p>
3:30pm – 4:00pm 4:00pm – 5:30pm Afternoon Tea - BioIndustry Exhibition Hall - Sponsored by Government of Canada / Province of Manitoba				
<p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p style="text-align: center;">GENERAL Room 220</p> <p>What makes the Media tick?</p> <p>Insights from industry and mainstream journalists to help delegates understand how the news cycle works</p> <p>What do the media need from Companies to get a story in the papers; i.e breaking news; access to patients ; movement in share price for a business/investment story. Why is there resistance to biotech stories from mainstream outlets and how can this be overcome?</p> <p>How can the industry help media to understand the stages of clinical trial development?</p> <p>Chair: Dr Fintan Walton, Chief Executive & Founder, PharmaVentures, UK</p> <p>Panelists: Mr Nick Evans, Editor, Biotechnologynews.net, Aspermont Ltd</p> <p>Mr Steven Edelson, Executive Editor, SciBX</p> <p>Ms Rebecca Wilson, Principal, Buchan Consulting</p>	<p style="text-align: center;">HUMAN HEALTH Room 218</p> <p>Health Technologies; helping to solve poverty in Asia and Africa</p> <p>Developing "appropriate" technologies to meet the needs of the rural poor in Asia and Africa.</p> <p>Chair: Dr Graeme Woodrow, Chief, CSIRO Molecular and Health Technologies</p> <p>Speakers: Dr Nick Day, Professor of Tropical Medicine, Oxford, and Director of the Mahidol Oxford Clinical Research Unit, Bangkok, Thailand. <i>"Integrating appropriate diagnostics and clinical epidemiology to provide effective community-wide response to infectious diseases"</i></p> <p>Dr. Ram A. Vishwakarma, Ph.D, Director, Indian Institute of Integrative Medicine (CSIR), Jammu, India. <i>"Open Source Drug Discovery (OSDD): a new Indian-led initiative for the development of drugs against neglected diseases"</i></p> <p>Dr Rens Scheepers, Associate Professor, Department of Information Systems, The University of Melbourne <i>"Mobile phone applications that assist health workers in developing countries diagnose disease and improve care"</i></p>	<p style="text-align: center;">AG / INDUSTRIAL / FOOD Room 217</p> <p>Successful Models for Building a Sustainable Future Bioeconomy</p> <p>At a time when sustainability is a mantra, agricultural and industrial biotechnology hold great hope for the development of food production, manufacturing and delivery processes that limit the depletion of scarce resources.</p> <p>The Government of Manitoba in Canada, has strategically fostered relationships with several regions in Australia, building linkages with government, policy makers, the scientific community and industry to mobilise shared resources and more quickly commercialise vital technologies.</p> <p>The session will discuss ideas and models for jointly building a sustainable bioeconomy through visionary direction from government and strategic international partnerships.</p> <p>Chair and Speaker: Mr Doug McCartney, Director - Science, Innovation & Business Development, Manitoba Govt <i>"Manitoba, building a sustainable bioeconomy through collaboration"</i></p> <p>Speakers: Mr Peter Benders, President & CEO, BIOTECANADA <i>"Building a sustainable bioeconomy - the Canadian perspective"</i></p>	<p style="text-align: center;">INVESTMENT / BUSINESS Room 219</p> <p>Global Regulatory Challenges and Opportunities</p> <p>Global regulatory challenges require a consistent and integrated approach to biotechnology products, with regional considerations. Sponsors are exploring the promises and opportunities available in the Asian Pacific region. This session will bring together consultants and corporate experts for an overview of challenges and opportunities of these programs.</p> <p>Chair: Dr Judy Bingham, Senior Director, Regulatory Consulting and Submissions Asia Pacific. Kandle</p> <p>Speakers: Dr Evan Siegel, President and CEO, Ground Zero Pharmaceuticals, USA. <i>"Global Regulatory Strategy: The Asian Pacific Region"</i></p> <p>Dr Michael Greenberg, Clinical Program Director, Vaccines Development, CSL</p> <p>Dr Paul Tan, Chief Executive Officer, LCT <i>"Meeting international guidelines for first-in-human cell therapy"</i></p>

			<p>Mr Sean McKay, Executive Director, Composites Innovation Centre, Canada <i>"Building a sustainable Composite Materials bioeconomy"</i></p> <p>Dr. Curtis Rempel, Research Development Manager, University of Manitoba. <i>"Building a sustainable agri-health bioeconomy"</i></p> <p><i>Sponsored by Province of Manitoba</i></p>	
5:30pm – 7:00pm	<p>INTERNATIONAL RECEPTION BioIndustry Exhibition Hall Welcome delivered by Mr Douglas McCartney, Senior Executive Director, Manitoba Science, Innovation, and Business Development and Ms EllenRuth Zeisler, Canadian Senior Trade Commissioner, Consulate General of Canada, Sydney</p> <p>Sponsored by Government of Canada / Province of Manitoba</p>			
7:00pm – 8:00pm	<p>AusBiotech 2009 Major Partners VIP Reception - <i>by invitation only</i> <i>Clarendon Room, Level 5, Melbourne Exhibition Centre</i></p>			

THURSDAY 29 OCTOBER

7:30am – 8:30am	<p>PwC Breakfast, by invitation only – Room 212, Level 2, MCC US takeovers: Good or bad for the local biotech sector? Breakfast briefing on Cephalon's \$300m takeover of Arana.</p>			
9:00am – 5:30pm	<p>BIOINFORMATICS AUSTRALIA CONFERENCE – BA2009 – Room 213, Level 2, MCC</p>			
9:00am – 11:00am	<p>PLENARY 3 - Millis Oration – Introduced by Dr Andrew Cuthbertson, Director of R&D and Chief Scientific Officer, CSL. Sponsored by CSL "CSIRO's part in boosting the growth of the biotechnology sector" Dr Megan Clark, Chief Executive, CSIRO, Australia</p> <p>PLENARY 4 – "Genomics and the Next Phase of Biotechnology" Dr Ganesh Kishore, CEO, Malaysian Life Sciences Capital Fund, Burrill and Company / Malaysian Technology Development Corporation, United States</p> <p><i>Room 220, Level 2, Melbourne Convention Centre</i></p>			
11:00am – 11:30am	<p>Morning Tea – Sponsored by CSL - BioIndustry Exhibition Hall</p>			
<p><i>11:30am – 1:00pm</i></p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>MEDTECH Room 218</p> <p>Medical Devices Regulatory: Supplier compliance management in an outsourced world.</p> <p>With ever increasing reliance on outsourced functions, including low cost manufacture and of sub contract of key services ranging from sterilization and packaging to consulting services, the control of suppliers is of central importance for device manufacturers. It is essential to set up the contractual relationships so that they cover not only commercial terms</p>	<p>HUMAN HEALTH Room 220</p> <p>Funding Opportunities to Support Biotech R&D in Infectious Disease</p> <p>This session will provide an overview of the funding opportunities available to support R&D in infectious disease. Panelists will represent government, industry, and venture capital, and will provide a unique perspective on each respective approach for support of novel biotechnologies.</p> <p>Chair and Speaker: Dr Jennifer</p>	<p>AG / INDUSTRIAL / FOOD Room 217</p> <p>Biotech in Australian Agricultural Cropping</p> <p>Biotechnology has been part of the Australian cropping system since the introduction of GM cotton in 1996. Following a presentation on developments in the area, a farmer will discuss his experiences with GM canola followed by a presentation on the use of GM in the horticulture industry.</p>	<p>INVESTMENT / BUSINESS Room 219</p> <p>Changing Business Models and New Financial Opportunities</p> <p>Small, early stage biotech companies are struggling to raise funding forcing them to cut costs and rethink their business models. Many are looking at earlier stage partnering, outsourced research and BD roles and convertible notes or other alternative sources of funding. A viable way forward for these biotech's will be discussed.</p>

	<p>but also clearly identify shared responsibilities for quality and regulatory compliance. This session includes the views of manufacturer, the contractor and of the regulatory body and their approach to audit of supplier controls. It will focus on practical measures to select, assess, qualify and monitor your key suppliers.</p> <p>Chair: Mr Paul Cohen, Senior Consultant, Brandwood Biomedical</p> <p>Speakers: Dr Adrian Oates, Vice President of Quality and Regulatory, Universal BioSensors <i>"Experience of selecting and controlling key suppliers (and on being a supplier in turn to a Multinational partner)"</i></p> <p>Mr Richard Walmsley, CEO, Ingeneus <i>"Experience as a contract supplier – what are the key factors to assisting clients meet regulatory requirements"</i></p> <p>Dr. Peter Havel, Director MHS Group, TÜV SÜD Japan Ltd. <i>"Regulatory requirements for control of key suppliers – the approach of the assessor"</i></p>	<p>Hanneschlager, Managing Scientific Director, McKenna Long & Aldridge LLP, United States <i>"Leveraging the Non-Dilutive Capital of the United States Government to Maximize Opportunities in Biotechnology and Infectious Disease"</i></p> <p>Dr Jane Ryan, Vice President of Product Development, Biota Holdings Ltd <i>"Funding opportunities to support R&D an industry perspective"</i></p> <p>Dr Benjamin P. Chen, Managing Director, Burrill & Company, San Francisco</p> <p>Dr Sarah Holland MBA , Global Head, CNS Partnering, Pharma Partnering, Hoffmann-La Roche</p>	<p>Chair: Mr Keith Glasson, General Manager, Pioneer Hi-Bred Australia</p> <p>Speakers: Dr Andrew L.D. Walter, Operations Manager, AH & GM Walter Pty Ltd <i>"GM Canola – The Australian Farmer's experience to date and future directions"</i></p> <p>Dr Steve Chandler – General Manager, Florigene <i>"Commercialisation of genetically modified ornamental plants"</i></p> <p>Mr David Hudson, Managing Director, SGA Solutions Pty Ltd <i>"What is in the agricultural biotechnology pipeline for Australian Agriculture?"</i></p> <p>Dr. Gary Fitt, Deputy Chief, CSIRO Entomology <i>"Environmental and economic impact of Bt cotton in Australia"</i></p>	<p>Chair: Dr Stewart Washer, Director, AusBiotech Ltd</p> <p>Panelists: Mr Hershel Berry, Founder & Managing Partner, Blueprint Life Sciences</p> <p>Dr Graeme Wald, Head of Life Sciences Research, Wilson HTM</p> <p>Mr David Blake, Co-Editor, Bioshares</p> <p>Mr Lawrence Gozlan, CEO & Founder, Scientia Capital</p> <p>Mr Scott Power, Associate Director, Research, ABN AMRO Morgans Limited</p> <p>Dr Elliot Parks, President & CEO, Hawaii Biotech Inc</p> <p>Mr Matt McNamara Chief Investment Officer, IB Fund</p>
<p>12:45pm – 2:00pm</p>	<p>Ernst and Young Global Report Luncheon Room 212, Level 2, Melbourne Convention and Exhibition Centre Ernst & Young is pleased to invite you to the 2009 Beyond Borders Global Biotech Report Mid-Year Update luncheon. Scott Sarazen, Ernst & Young's Boston based Global Life Sciences Markets Leader and Winna Brown, Australian Life Sciences leader, will highlight the industry's four emerging paradigm-shifting trends that are expected to lead to new, more sustainable ways of funding drug development. This session will also take a look at the global and Australian biotech sectors six months on - how has the industry fared in light of the continued global economic turmoil?</p>			
<p>1:00pm – 2:00pm Lunch –Sponsored by the Victorian Government - BioIndustry Exhibition Hall</p>				
<p>2:00pm – 3:30pm</p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>MEDTECH Room 218</p> <p>In Vitro Diagnostics: New Technologies, New Markets, New Regulations, New Risks?</p> <p>Rapid developments in technology are producing new diagnostics which offer great promise in areas ranging from population screening to personalised medicine. However these technologies bring new challenges in public health, funding and ethics and regulatory systems are evolving rapidly in response. This session looks at the challenges in developing a new IVD and the proposed new regulatory frameworks both in Australia and internationally.</p>	<p>HUMAN HEALTH Room 220</p> <p>The challenge and opportunity of targeted therapies</p> <p>The tools of biotechnology are used to develop innovative drugs that will make a meaningful difference in the lives of patients. Application of cutting-edge science and technology is making earlier, better, more informed decisions in its development of therapeutics.</p> <p>Treatment, prevention and detection will be guided by the use of more effective "biomarkers". New biomarkers that help to monitor therapy, and serve to identify and select patients that are more likely to respond,</p>	<p>AG / INDUSTRIAL / FOOD Room 219</p> <p>Biofuels</p> <p>While the biofuels industry in Australia is still in its relative infancy, growth in the sector is rapidly gaining momentum. Australian governments are increasingly recognising the need to encourage and support research and development of biofuels manufactured from non-food sources that will achieve sustainable long term benefits to the environment and the Australian community. This session will provide an overview of Australia's capabilities in the development and commercialisation of second generation</p>	<p>INVESTMENT / BUSINESS Room 217</p> <p>Valuing and Commercialising Intellectual Property</p> <p>The valuation and commercialization of Intellectual Property is difficult at the best of times, particularly where there are long paths to market. The Global Financial Crisis has added salt to the wounds. This session will examine valuation and commercialization of IP from three different view points: - A financial valuer; - A solicitor dealing with licensing and commercialization ; and - A biotech investor</p>

	<p>Chair: Dr Mervyn Thomas, Managing Director, Emphron Informatics</p> <p>Speakers: Dr Jenny Harry, CEO Tyrian Diagnostics <i>"Commercialising IVDs in a changing regulatory framework"</i></p> <p>Dr Susan Alder, Consultant, SJ Alder Pty Ltd <i>"The New IVD legislation"</i></p> <p>Dr Arthur Brandwood, Managing Director, Brandwood Biomedical Pty Ltd <i>"An Uncertain Diagnosis – Global Regulatory Consensus for IVDs?"</i></p> <p style="text-align: center;"><i>Sponsored DevDx Clinical</i></p>	<p>are a focus of current efforts. However the best way to integrate these approaches into clinical and regulatory strategies continues to evolve.</p> <p>Chair: Dr Deborah Campbell, Executive Medical Director, Amgen Australia</p> <p>Speakers: Dr C. Glenn Begley, Vice President, Hematology Oncology Research, Amgen <i>"Biomarkers as patient stratification markers"</i></p> <p>A/Prof David Thomas, Peter MacCallum Cancer Research <i>"Imaging biology of response to treatment in clinical studies"</i></p> <p>Dr Niall Tebbutt, Consultant Medical Oncologist, Ludwig Institute for Cancer Research <i>"EGFR targeted therapies in colorectal cancer"</i></p> <p style="text-align: center;"><i>Sponsored by AMGEN</i></p>	<p>biofuels, with a focus on research activities directed at delivering commercial outcomes from renewable resources, as well as an end-user's perspective of the industry.</p> <p>Chair: Dr Les A Edey, Principal Research Fellow, Biofuels & Biorefineries, Queensland University of Technology</p> <p>Speakers: Dr Tom Beer, President, IUGG, Leader - IYPE Hazards Theme, Transport Biofuels Stream Leader, Energy Transformed Flagship, CSIRO <i>"CSIRO Biofuels Research on Lignocellulosic and Algal Feedstocks"</i></p> <p>Mr Ian O'Hara, Senior Research Scientist and Theme Leader, BioEnergy, QUT <i>"QUT Progress towards the development of a commercial cellulosic ethanol industry in Australia - infrastructure and innovation"</i></p> <p>Mr Brad Wheatley, Research Leader, Environment, Boeing Australia <i>"Sustainable Aviation Biofuels"</i></p> <p style="text-align: center;"><i>Sponsored by NCRIS</i></p>	<p>Chair and speaker: Mr Peter Francis, Partner, Francis Abourizk Lightowlers</p> <p>Speakers: Mr Hamish Blair, Senior Adviser, Leadenhall VRG <i>"Critical issues in valuing IP – Identifying and quantifying the 'moving parts' "</i></p> <p>Dr Andrew Kelly, Executive Director, BioPacificVentures, New Zealand <i>"The golden rules of valuing and commercialising IP"</i></p>
--	---	--	---	---

3:30pm – 4:00pm	Afternoon Tea - BioIndustry Exhibition Hall				
4:00pm – 5:30pm	GENERAL Room 218	GENERAL Room 212	HUMAN HEALTH Room 220	AG / INDUSTRIAL / FOOD Room217	INVESTMENT / BUSINESS Room 219
<p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>Regional Collaboration</p> <p>This session will include presentations pertaining to regional collaboration, emerging markets, improving regional cooperation in particular strategies in harmonisation of regulatory systems, business to business information sharing, ways of improving business interactions across country borders, technology hubs and regional challenges and</p>	<p>Careers Catwalk</p> <p>The AusBiotech 2009 Conference 'Careers Catwalk' will showcase a variety of positions available within the field of biotechnology and will include presentations by inspirational figureheads holding diverse positions within the sector. It will also provide the opportunity for students to put their questions to key professionals within the industry as well as increase their</p>	<p>Product Development and Regulatory Aspects in Asia Pacific</p> <p>This session will address how the regulatory agencies in Japan, Korea and Australia have responded to the biopharmaceutical industry's interest to expand the number of clinical trials in the Asia-Pacific region and how these changes are viewed by other agencies. In addition, the acceptability of foreign clinical data from trials involving biotech compounds will be discussed.</p> <p>Chair: Dr Christopher J. Holloway, CSO, ERA Consulting Ltd, United Kingdom</p> <p>Speakers: Ms Ana Maria Moreno, Research Associate, Corelli Consulting <i>"Looking over the fence: drivers behind the</i></p>	<p>Biosecurity</p> <p>Like many island nations, Australia is constantly exposed to plant and animal diseases through trade. As both inbound and outbound trade increases, the likelihood of disease outbreaks will also increase. This session provides an overview of biosecurity issues in Australia, with a focus on plant and animal diseases, the contribution that biotechnology is making in protecting the Australian environment and how some of these technologies are commercialised.</p> <p>Chair: Professor John Lovett, Chairman, Cooperative Research Centre for National Plant Biosecurity</p> <p>Speakers: Professor Tony Peacock, CEO, Invasive</p>	<p>Maximising value: How tough markets are reshaping the business models of big pharma and venture capital and biotechnology companies</p> <p>Business model structuring of big pharma and venture capital organisations is facing a period of transition. The end result of this transition depends on how long this financing stagnation to initial public offerings (IPOs) of drug discovery and development companies will last. Take this opportunity to hear from those at the forefront of change in Asian-Pacific markets and learn how current economic conditions are driving values of deals and acquisitions.</p> <p>Chair: Mr Peter Sandbach, Head of</p>

	<p>opportunities</p> <p>Chair: Dr Anna Lavelle, CEO, AusBiotech</p> <p>Speakers:</p> <p>Dr Zeqi Zhou, Vice President Tianjin International Joint Academy of Biotechnology and Medicine(TJAB), P.R. China</p> <p>Dr. Tran Ngoc Ca, Deputy Director, National Institute for S&T Policy and Strategy, Ministry of Science and Technology & Director, Secretariat, National Council for S&T Policy, Vietnam</p> <p>Dr. Thomas Diefenthal, CEO BioPark Regensburg Germany "<i>BioRegions and BioParks in Germany - example of international cluster development from Regensburg, Bavaria/Germany</i>"</p>	<p>knowledge of career options and pathways.</p> <p>Chair: Mr Andrew Macdonald, CEO, Cytopia Ltd</p> <p>Panelists: Dr Stella Clark, CEO, The Bio21 Cluster</p> <p>Ms Sue MacLeman, CEO, Benitec Ltd</p> <p>Ms Joy Hewitt, Director, Business Development, Biota Holdings Ltd</p> <p>Dr Danielle Smith Project Manager Medicines Development Ltd</p> <p><i>Sponsored by the Victorian Government</i></p>	<p><i>interest in foreign clinical trials by pharma in Japan and Korea</i></p> <p>Dr Zaheer Anjum, Acting Head, Office of Prescription Medicines, TGA <i>"Current Regulation of Clinical Trials in Australia"</i></p> <p>Dr Dianne Jackson-Matthews, Deputy Group Director of Regulatory Affairs, ERA Consulting, Australia <i>"Leveraging Regulatory Opportunities for Biotech Development in the Asia-Pacific: Case Studies"</i></p>	<p>Animals CRC <i>"Twenty first century ferals"</i></p> <p>Dr Robyn Lindner, CSO, Tyrian Diagnostics <i>"Developing rapid point of need testing for crop quality."</i></p> <p>Mr Andrew Geering, Principal Plant Pathologist, Industry Services Queensland Primary Industries and Fisheries "<i>High throughput plant virus detection via multiplexed bead-based immunoassays</i>"</p> <p>Dr Linfa Wang, CEO Science Leader, CSIRO Livestock Industries. <i>"Bats and emerging zoonotic viruses"</i></p> <p><i>Sponsored by CRC for National Plant Biosecurity</i></p>	<p>Communications, Roche Pharma Partnering</p> <p>Panelists: Dr Bardia Akbari, Global Head Partnering Inflammation and Autoimmune - Roche</p> <p>Dr Geoff Brooke, Managing Partner & Co-Founder, GBS Venture Partners</p> <p>Mr Stephen Walters, Chief Economist, J.P. Morgan</p> <p>Dr Leigh Farrell, Vice President Business Development, Biota Holdings Ltd</p>
--	--	---	--	--	--

7:00pm – 11:30pm	<p>AUSBIOTECH 2009 CONFERENCE DINNER <i>Melbourne Convention and Exhibition Centre – Rooms 201 & 202, Level 2.</i> Sponsored by Pfizer</p>
------------------	--

FRIDAY 30 OCTOBER

9:00am – 1:00pm	BIOINFORMATICS AUSTRALIA CONFERENCE – BA2009 – Room 213, Level 2, MCC			
9:00am – 9:30am	<p>PLENARY 5 – 'Making sense of impending tax changes' Mr Sergio Duchini, Partner & National Leader R&D Taxes & Incentives/Co. Director, Deloitte Ms Sandra Buth, Principal, Global Employer Services/Reward, Deloitte Chaired by Dr Anna Lavelle, CEO, AusBiotech, Ltd <i>Melbourne Convention Centre – Room 220, Level 2.</i></p>			
9:30am – 11:00am	<p>GENERAL Room 218</p> <p>Thriving and surviving in these economic</p>	<p>HUMAN HEALTH Room 217</p> <p>Making your company attractive to big</p>	<p>AG / INDUSTRIAL / FOOD Room 219</p> <p>CleanTech</p>	<p>INVESTMENT / BUSINESS Room 220</p> <p>Licensing / Strategic Deal Terms</p>
Concurrent Sessions: Level 2 Melbourne				

*Conference Program as at 27 October - subject to change

<p>Convention Centre</p>	<p>times - an international perspective</p> <p>Whilst the current global financial crisis presents a level of uncertainty, it also offers opportunities that should be maximised to ensure future growth. Our team of speakers (both with corporate and intellectual property experience) will provide an international perspective on the key challenges faced by the industry and some of the strategies that should be implemented to leverage opportunities and minimise risk.</p> <p>Chair: Mr Tony Conaghan, Practice Group Leader, Intellectual Property and Technology Practice, DLA Phillips Fox, Australia</p> <p>Speakers: Dr Lisa A. Haile, J.D., Partner, Life Sciences Practice, DLA Piper, United States <i>"Life Sciences Market Trends-A Perspective on the Biotech and Pharma Industry in the United States"</i></p> <p>Dr Graeme Wald, Head of Life Sciences Research, Wilson HTM</p> <p>Mr Sajai Singh, Resident Partner, J.Sagar Associates, India</p> <p><i>Sponsored by DLA Phillips Fox</i></p>	<p>pharma – marriage or rejection!</p> <p>Chair and Speaker: Dr Greg Wiederrecht, Vice President and Head, External Scientific Affairs, Merck Sharp and Dohme <i>"Tips for Getting the Attention of Pharma - the Big Pharma Perspective"</i></p> <p>Speakers: Dr Mark Heffernan, CEO, OPSONA Therapeutics Ltd <i>"A small biotech's perspective in a big pharma marriage – who wears the pants?"</i></p> <p>Dr Deborah Rathjen, CEO & Managing Director, Bionomics Limited <i>"Getting to yes: managing the Pharma beauty parade"</i></p> <p><i>Sponsored by Merck Sharpe and Dohme</i></p>	<p>The focus of this session will be on how advanced biological systems and novel biomaterials can be applied across a range of industries to deliver environmental outcomes. The session will provide an overview of what technologies are available, detail of some of the technologies, how they can deliver improvements to industrial processes, resource efficiencies and the remediation of land, air and water environments, including the commercialisation of the technology or process.</p> <p>Chair: Mr Dale Seymour, Deputy Secretary, DIIRD</p> <p>Mr Geoff Bell, CEO, Microbiogen <i>"Microbiogen's Biomass to Food and Fuel Concept"</i></p> <p>Mr Jeffrey Castellias, CEO, Clean Technology AustralAsia Pty Ltd <i>"Cleantech: deployment and investment opportunities for Australia"</i></p> <p>Ms Kate Phillips, Senior Associate, Baker & McKenzie</p> <p><i>Sponsored by Victorian Government</i></p>	<p>Getting the "right" deal done.</p> <p>This panel will cover practical advice for structuring, negotiating and executing your next strategic alliance. The discussion will include the synthesis of range of topics including: using competitive intelligence to reduce the asymmetry of knowledge, understanding and communicating the value of your programs, structuring with a strategic focus and managing the deal process.</p> <p>Chair: Mr Ian Edvalson, Partner, Wilson Sonsini Goodrich and Rosati, California, United States</p> <p>Speakers: Mr Lubor Gaal, Head of Europe Search, Strategic Transactions Group, Bristol-Myers Squibb</p> <p>Dr Leigh Farrell, Vice President Business Development, Biota Holdings Ltd <i>"Dancing with gorillas in tough times: reducing the knowledge asymmetry gap and alternative deal structuring options"</i></p> <p>Ms Robin Coleman, Director, PharmBio Deals</p>
--------------------------	--	--	--	---

<p>11:00am – 11:30am Morning Tea - BioIndustry Exhibition Hall</p>				
<p>11:30am – 1:00pm</p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>MEDTECH Room 218</p> <p>Creating Product Excitement - and Global Competitive Advantage</p> <p>Developing products for the modern global healthcare market takes more than great engineering and science. Companies using design best practice emanate a culture of success. Design builds reputations, design differentiates you from competitors and design protects your hard-earned business assets.</p> <p>More importantly, design culture provides the environment for innovation and change that creates the market leaders - and others can only follow.</p>	<p>HUMAN HEALTH Room 219</p> <p>Clinical Trials</p> <p>Australia is facing increasing competition from other emerging countries in the area of clinical trials. This session will look at some of Australia's unique capabilities, discuss the future of the clinical trials industry, and report on the benchmarking survey of industry sponsored clinical research in Australia.</p> <p>Chair: Ms Kerry Doyle, Acting Executive Director, Innovation, Research and Policy, Industry and Investment NSW</p> <p>Speakers: Ms Lynda Shelley, Executive Director Clinical Operations, Novotech</p>	<p>AG / INDUSTRIAL / FOOD Room 217</p> <p>Taking functional foods to market</p> <p>The interest in functional foods is increasing. With the FDA recently calling a fortified breakfast cereal a drug, how can foods with beneficial health outcomes be commercialised without stepping over the line. This session will look at some foods in development, review foods that have been commercialised and look at where functional foods are headed next.</p> <p>Chair: Mr Peter R. Schutz, Chief Executive, George Weston Technologies</p> <p>Speakers: Dr Ross Crittenden, R&D manager,</p>	<p>INVESTMENT / BUSINESS Room 220</p> <p>Effective Means of Commercialising in India and China</p> <p>The session will have wide coverage including researcher collaborations, seeking commercial investment, pharma partnering and IP strategy. The research section will focus on CSIRO's experience through the Australian India Biotech Partnership and student exchanges with China. Pharma will be represented by a regional BD person or, if travel does not permit, one of their local counterparts. We are seeking a venture or industry incubator that invests in Asia. Griffith Hack will present on China specific collaboration and potential IP pitfalls.</p>

	<p>Chair: Mr Richard Walmsley, CEO, Ingeneus</p> <p>Speakers: Mr Grant Davidson, Managing Director, Davidson <i>"Great companies make great products - great brands make great user experiences."</i></p> <p>Dr Fred Davis, Managing Director, Invetech <i>"Commercial Success from New Product Development - Shaping Winning Solutions"</i></p> <p>Mr Trevor Choy, Founder, Choy Lawyers <i>"Prepare to be ripped-off – and win"</i></p> <p><i>Sponsored by Design Victoria</i></p>	<p><i>"Trends in clinical trials and strategies for the future"</i></p> <p>Dr Andrew Martin, Senior Lecturer, Biostatistics, NHMRC Clinical Trials Centre <i>"Building clinical trials capacity in Australia"</i></p> <p>Dr Melissa Grady, Co-Chair, Pharmaceutical Industry Council Research and Development Taskforce <i>"The PIC benchmarking study"</i></p> <p>Mr Craig Rogers, Chief Commercial Officer, Nucleus Network <i>"What has made Australia an attractive site to conduct Early Phase Clinical Research for overseas sponsors and how can this international experience assists local biotechs"</i></p> <p><i>Sponsored by Industry & Investment, NSW Government</i></p>	<p>Biologics and Nutrition, MG Nutritionals, Project Leader, CSIRO Food and Nutritional Sciences <i>"ASCEND sports protein supplements: launching a brand based on science into a world of hype"</i></p> <p>Dr Ebenezer Satyaraj, Senior Research Scientist, Nestle Research Center, St. Louis, MO, USA <i>"Nutrition and the Immune System: Advances, Implications and a Case Study in 'Research to Retail'."</i></p> <p>Dr Bruce Lee, Director, Food Future Flagship, CSIRO</p> <p>Ms Lynn Ferguson, Head, Discipline of Nutrition, Faculty of Medical and Health Sciences, The University of Auckland <i>"Is the marketplace ready for nutrigenomic foods"</i></p>	<p>Chair: Ms Kiara Bechta-Metti, Commercialisation Manager, CSIRO</p> <p>Speakers: Dr Daniel Grant, Head of R&D Business Development, Australia, New Zealand, Singapore, Pfizer Global Research and Development</p> <p>Mr Robert Wulff, Principal, Griffith Hack <i>"Taming the Dragon, Dealing in IPRs in China"</i></p> <p>Dr Phil Kearney, Licensing & External Research, Merck, Sharpe and Dohme. <i>"Sourcing Innovation in Asia Pacific"</i></p>
<p>1:00pm – 2:30pm AUSBIOTECH 2009 CLOSING RECEPTION and WELCOME TO AUSBIOTECH 2010 Includes lunch and features Victorian Regional Wine Tasting BioIndustry Exhibition Hall</p>				
<p>2:30pm – 3:30pm</p>	<p>AusBiotech Ltd Annual General Meeting <i>Melbourne Convention and Exhibition Centre – Room 220, Level 2</i> All AusBiotech members are encouraged to attend and participate at the Annual General Meeting</p>			